PARP1 and pachyonychia congenita: Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) are a novel class of anticancer therapeutics that have become part of standard treatment for breast and ovarian cancers carrying BRCA mutations and represent a therapeutic option for treatment-refractory PC.